New Delhi: Bharat Biotech’s COVID-19 vaccine, which has been authorised to be used in the country, is proven to be safe and produced an immune response in a small group of adults in the age group 18-55 years, a study in The Lancet medical journal said.
The vaccine, developed in association with the Indian Council of Medical Research (ICMR), is being evaluated in a separate 25,800 person trial, that kicked off in November. Bharat Biotech on Friday said that 13,000 people taking part in the late-stage trial had been given the second dose, reported news agency Reuters.
Two formulations of the vaccine, called COVAXIN, have been picked for testing in more advanced stages and further efficacy trials are warranted, the agency report said.
COVAXIN is an inactivated vaccine that introduces dead virus into the body to trigger an immune response.
ALSO READ: India To Start Exporting COVID-19 Vaccines To Six Neighbouring Countries Today
New Delhi: In a recent statement that has stirred political conversations, Shashi Tharoor reaffirmed his… Read More
Bhopal: Prime Minister Narendra Modi lashed out at critics of the Mahakumbh Mela at a… Read More
Balasore: With the festival of Maha Shivratri fast approaching, hectic preparations are underway at the… Read More
New Delhi: In a recent social media post, actress Kangana Ranaut sparked controversy by defending… Read More
Dubai: India restricted Pakistani to a manageable total in their Group A Champions Trophy clash,… Read More
Bhubaneswar: Hundreds of turtles being transported illegally were seized from a vehicle in Godipada area… Read More
This website uses cookies.
